The study of Pharmacoeconomics analysis on anti tuberculosis drugs Rifampicin & Ethambutol
Keywords:
Pharmacoeconomics, TB drugs, Anti-tuberculosis, clinical pharmacy, COI, CBAAbstract
Cost-benefit analysis can be used to quantify the value of clinical pharmacy services. Providing Effective Therapy and Minimum cost, Quantify costs of care, Quantify outcomes, Assess whether and by how much average costs and outcomes differ among treatment groups, Compare magnitude of difference in costs and outcomes and evaluate “value for costs” by reporting a cost-effectiveness ratio, net monetary benefit, or probability that ratio is acceptable – Potential hypothesis: Cost per quality-adjusted life year saved significantly less than Rs.75,000, To Perform sensitivity analysis. For providing good effective therapy with less adverse drug reaction at affordable price, Cost-Identification, Cost-Effectiveness Analysis, Cost-Utility Analysis, Cost-Benefit Analysis, Clinical outcomes: Cure, comfort and survival, Humanistic outcomes: Physical, emotional, social function, role performance, Economic outcomes, Economic Evaluation, Cost of Illness Evaluation (COI), Cost Benefit Analysis (CBA), Cost Minimization Analysis, Cost Effective Analysis: Cost Utility Analysis.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2019 Arsalan Sarmad, B. Syed Salman, Syed Sharfuddin Ibrahim
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.